EAM
MBX

Eventide Asset Management’s MBX Biosciences MBX Stock Holding History

Eventide Asset Management’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.2M Sell
873,492
-16,508
-2% -$577K 0.64% 52
2026
Q1 		$26.6M Hold
890,000
– – 0.44% 79
2025
Q4 		$28.1M Buy
+890,000
New +$21.6M 0.44% 82

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $328M AUM 166.51% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Eventide Asset Management's MBX Position: Q2 2026 in Review

Eventide Asset Management reduced its MBX Biosciences (MBX) stake by 1.9% in Q2 2026, selling an estimated $577K and leaving 873,492 shares worth $48.2M. The position accounts for 0.64% of the portfolio, ranked #52.

Eventide Asset Management first reported a position in MBX in Q4 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold MBX as of Q2 2026.

  • Eventide Asset Management held 873,492 shares of MBX Biosciences worth $48.2M as of Q2 2026.
  • Eventide Asset Management sold 16,508 MBX Biosciences shares in Q2 2026, an estimated $577K.
  • MBX Biosciences made up 0.64% of Eventide Asset Management's portfolio in Q2 2026, its #52 holding.
  • Eventide Asset Management first reported a position in MBX Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 173 funds tracked by Wall St. Rank held MBX Biosciences as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.